Rahul Sarna, MD
Interventional Pain Medicine · San Marcos, TXNPI 1184987174
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Foundation Fusion Solutions, LLC at 47.1% of the total. Reporting peaked in 2022 at $19,963 and has fallen 94.9% since, to $1,019 in 2025.
Across 374 payments — averaging $80.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Fusion Solutions, LLC$14K
- Abbott$7K
- Boston Scientific$3K
- Relievant Medsystems, Inc.$2K
- Si-bone, Inc.$687
- Painteq LLC$561
- plus $3K from 21 others
What the payments were for
- Consulting fees$12,75043%
- Travel & lodging$4081%
- Food & beverage$16,37655%
- Education$3201%
- Entertainment$1040%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Foundation Fusion Solutions, LLC | 19 | $14,097 |
| Abbott | 191 | $7,376 |
| Boston Scientific | 59 | $2,516 |
| Relievant Medsystems, Inc. | 15 | $1,575 |
| Si-bone, Inc. | 10 | $687 |
| Painteq LLC | 9 | $561 |
| Bioventus LLC | 6 | $512 |
| Globus Medical | 5 | $495 |
| Nevro Corp. | 4 | $462 |
| Medtronic(2 entities) | 9 | $414 |
| Vertiflex, Inc. | 9 | $300 |
| Nalu Medical, Inc. | 9 | $298 |
| Vertos Medical, Inc. | 1 | $110 |
| Spinal Simplicity, LLC | 5 | $93 |
| Collegium Pharmaceutical, Inc. | 6 | $85 |
| SPR Therapeutics, Inc | 2 | $82 |
| Johnson & Johnson | 2 | $55 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Averitas Pharma Inc. | 1 | $24 |
| Shionogi Inc | 1 | $24 |
| Novartis | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| AbbVie | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$2,619
- PROCLAIM$2,061
- Proclaim IPG$722
- OCTRODE$529
- Omnia$421
- Stimrouter Implantable Kit$413
- Senza$405
- PAINTEQ$240
- GENERAL - THERAPIES$239
- GENERAL PAIN MANAGEMENT$233
- iFuse Implant$135
- INTELLIS$134
- INTELLIS ADAPTIVESTIM$127
- SUPERION$118
- Proclaim Family of SCS IPGs$110
- mild Device Kit$110
- Nalu Neurostimulation System$103
- PAIN MANAGEMENT$102
How this compares
$29,958 in reported general payments places this provider in the 85th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nucynta ErTapentadol Hcl | 11 | $13,161 |
| Xtampza ErOxycodone Myristate | 26 | $13,103 |
| BelbucaBuprenorphine Hcl | 12 | $9,503 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 224 | $6,425 |
| NucyntaTapentadol Hcl | 11 | $4,871 |
| OxycontinOxycodone Hcl | 11 | $4,554 |
| Tramadol Hcl ErTramadol Hcl | 22 | $1,333 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 52 | $1,272 |
| Gabapentin | 111 | $1,206 |
| Pregabalin | 50 | $919 |
| Oxycodone Hcl | 66 | $873 |
| Morphine Sulfate ErMorphine Sulfate | 33 | $784 |
| Tramadol Hcl | 98 | $777 |
| Lidocaine | 12 | $562 |
| Methocarbamol | 51 | $339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er, Belbuca, Nucynta | $85 | $40,63960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in San Marcos
- Charles MouchSan Marcos$57K
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.1M
- Chad StephensSouthlake$1M
- Ankur KhoslaShenandoah$277K
- Brian RichDecatur$245K
- Brian BruelHouston$219K
- Bolkar SahinlerLubbock$188K
- Timothy RatinoFort Worth$139K
- Genaro GutierrezAustin$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.